Related content

Is there clinical utility to IL28B genotype testing in the treatment of chronic hepatitis C virus infection?

By Liapakis AnnMarie   Jesudian Arun B  

Pharmacogenomics, Vol. 13, Iss. 12, 2012-09 ,pp. : 1317-1319

Future Medicine

Access to resources Recommend Favorite

IL‐35: A potential therapeutic target for controlling hepatitis B virus infection

By  

Journal of Digestive Diseases, Vol. 16, Iss. 1, 2015-01 ,pp. : 1-6

John Wiley & Sons Inc

Access to resources Recommend Favorite

IL28B genetic variations are associated with treatment response of patients with chronic hepatitis C in a Chinese Han population

By  

Journal of Digestive Diseases, Vol. 16, Iss. 2, 2015-02 ,pp. : 90-97

John Wiley & Sons Inc

Access to resources Recommend Favorite

Single and combined IL28B, ITPA and SLC28A3 host genetic markers modulating response to anti-hepatitis C therapy

By Lötsch Jörn   Hofmann Wolf Peter   Schlecker Christina   Zeuzem Stefan   Geisslinger Gerd   Ultsch Alfred   Doehring Alexandra  

Pharmacogenomics, Vol. 12, Iss. 12, 2011-12 ,pp. : 1729-1740

Future Medicine

Access to resources Recommend Favorite

Emerging Therapeutic Strategies for Hepatitis C Virus Infection

By  

Current Molecular Pharmacology, Vol. 1, Iss. 2, 2008-01 ,pp. : 130-150

Bentham Science Publishers

Access to resources Recommend Favorite